The role of angiogenesis in neuroendocrine tumors

John Lyons 3rd; Catherine T Anthony; Eugene A Woltering

doi:10.1016/j.ecl.2010.08.006

The role of angiogenesis in neuroendocrine tumors

Endocrinol Metab Clin North Am. 2010 Dec;39(4):839-52. doi: 10.1016/j.ecl.2010.08.006.

Authors

John Lyons 3rd¹, Catherine T Anthony, Eugene A Woltering

Affiliation

¹ Department of Surgery, Louisiana State University, Health Sciences Center, New Orleans, LA 70112, USA.

PMID: 21095549
DOI: 10.1016/j.ecl.2010.08.006

Abstract

The first studies to assess in vitro angiogenesis in neuroendocrine tumors used animal-based assays to study the antiangiogenic properties of somatostatin analogs. Current technologies enable investigators to directly appraise the in vitro angiogenic response of an individual's neuroendocrine tumor with and without potential antiangiogenic reagents. This article describes the evolution of methods to assess in vitro angiogenesis in neuroendocrine tumors and describes some of the clinical data.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Animals
Humans
Models, Biological
Neovascularization, Pathologic / drug therapy
Neovascularization, Pathologic / genetics
Neovascularization, Pathologic / physiopathology*
Neuroendocrine Tumors / blood supply*
Neuroendocrine Tumors / drug therapy
Neuroendocrine Tumors / etiology*
Neuroendocrine Tumors / genetics
Receptors, Somatostatin / genetics
Receptors, Somatostatin / physiology
Somatostatin / analogs & derivatives
Somatostatin / genetics
Somatostatin / therapeutic use

Substances

Angiogenesis Inhibitors
Receptors, Somatostatin
Somatostatin